Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide Autogel in Symptomatic Polycystic Liver Disease
NCT01315795Phase 3Completed
- Sponsor
- UZ Leuven
- Start
- Mar 2011
- Primary completion
- Jul 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of lanreotide in Polycystic liver disease (PLD), sponsored by UZ Leuven. Started Mar 2011; status: completed.
02
Drugs
lanreotide
03
Conditions
Polycystic liver disease (PLD)
Beyond the preview
Go deeper on NCT01315795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01315795.